Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years-Reference-Cited by-同舟云学术

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years

Published:2021-06-26 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Kürzel Sabine,Blaudszun André-René^ORCID,Stahl Lilly,Herbst Regina,Kroschinsky Frank^ORCID,Birkmann Josef,Hänel Annette,Schaefer-Eckart Kerstin,Ehninger Gerhard^ORCID,Fiedler Friedrich,Bornhäuser Martin,Fricke Stephan,Hänel Mathias^ORCID

Funder

Carl Gustav Carus University Hospital of the Technical University Dresden

Klinikum Chemnitz gGmbH

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-021-03702-7.pdf

Reference59 articles.

1. Bannerji R, Allan JN, Arnason JE, Brown JR, Advani R, Ansell SM, O’Brien SM, Duell J, Martin P, Joyce RM, Li J, Flink DM, Zhu M, Weinreich DM, Yancopoulos GD, Sirulnik A, Chaudhry A, Ambati SR, Topp MS (2020) Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood 136:42–43. https://doi.org/10.1182/blood-2020-136659

2. Borchmann P (2020) Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma: final results of the international, randomized phase III HD17 trial by the GHSG. EHA Library:S101

3. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H-J, Willenbacher W, Ludwig W-D, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A (2017) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:2790–2802. https://doi.org/10.1016/S0140-6736(17)32134-7

4. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125–2132. https://doi.org/10.1200/JCO.2016.72.1316

5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244. https://doi.org/10.1200/JCO.1999.17.4.1244

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years;Journal of Cancer Research and Clinical Oncology;2022-09-09